Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMQ8J0U)

Drug Name

Basmisanil Drug Info

Synonyms

1159600-41-5; UNII-788PET5SUA; 788PET5SUA; (1,1-Dioxidothiomorpholino)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)methanone; Basmisanil [INN]; Basmisanil [USAN:INN]; Basmisani; Basmisanil(RG1662); Basmisanil (USAN/INN); SCHEMBL2685527; CHEMBL3681419; MolPort-044-561-818; VCGRFBXVSFAGGA-UHFFFAOYSA-N; BDBM133427; EX-A1272; AKOS032947142; ZINC145814743; DB11877; CS-6046; HY-16716; (1,1-Dioxo-4-thiomorpholinyl)(6-((3-(4-fluorophenyl)-5-methylisoxazol-4-yl)methoxy)pyridin-3-yl)metha

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]
Cognitive impairment	6D71	Phase 2	[2]
Complete androgen insensitivity syndrome	LD2A.4	Phase 2	[3]
Immune dysregulation	4A01.2	Phase 2	[3]

Cross-matching ID

PubChem CID: 57336276
CAS Number: CAS 1159600-41-5
TTD Drug ID: DMQ8J0U

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-5 (GABRA5)	TTNZPQ1	GBRA5_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
GABA(A) receptor alpha-5 (GABRA5)	DTT	GABRA5	4.883	0.926	1.536	4.365

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Alzheimer disease

ICD Disease Classification

8A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
GABA(A) receptor alpha-5 (GABRA5)	DTT	GABRA5	3.15E-09	-0.68	-0.61

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT02484703) A Study of RG1662 in Down Syndrome Among Children 6 to 11 Years of Age.
2	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)